CYDY CytoDyn

CytoDyn to Hold 2020 Virtual Annual Meeting of Stockholders on September 30, 2020

CytoDyn to Hold 2020 Virtual Annual Meeting of Stockholders on September 30, 2020

VANCOUVER, Washington, Sept. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reminds investors today the 2020 Virtual Annual Meeting of Stockholders will be held at 9:30 am PT on September 30, 2020. As stated in the Company’s proxy statement dated September 1, 2020, due to public health concerns relating to the coronavirus pandemic, stockholders will not be able to attend the Annual Meeting in person. The Company provides the following information as a reminder on how stockholders and guests can participate in the virtual meeting format:

Time: 9:30 am PT

Webcast login:

Stockholder questions: Submitted online via the meeting link, passcode CYDY2020 and their individual control number noted on their proxy card. Guests will not be able to submit questions during the meeting.

At the conclusion of the business portion of the meeting, Nader Pourhassan, Ph.D., President and Chief Executive Officer, will present an overview of the Company via a slide deck, which will be available on the Company’s website () at 9:30 am PT. In light of the limited amount of time for the meeting, stockholders are also encouraged to submit questions to management before 8:00 am PT tomorrow to: .

CYTODYN CONTACTS

Investors:

Michael Mulholland

Office: 360.980.8524, ext. 102

EN
29/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Co...

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite st...

 PRESS RELEASE

CytoDyn Releases ESMO Breast Cancer Meeting Poster

CytoDyn Releases ESMO Breast Cancer Meeting Poster VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today shared the Company’s poster presented at the European Society for Medical Oncology’s (“ESMO”) Breast Cancer meeting on May 14-17, 2025, in Munich, Germany. A copy of the poster is available at the following link: More information about the data CytoDyn presented at ESMO suggesting the novel mechanis...

 PRESS RELEASE

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronli...

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced new data suggesting a novel mechanism of action of leronlimab for th...

 PRESS RELEASE

CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial ...

CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E. Hoffman has been appointed as Chief Financial Officer, effective May 15, 2025. He will take over the CFO position from Mitch Cohen, who had been serving as CFO on an interim basis since February 2024. Mr. Hoffman is an industry veteran with decades o...

 PRESS RELEASE

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich...

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in attendance VANCOUVER, Washington, April 29, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, is pleased to announce that the Company will be presenting a poster at the upcoming European Society for Medical Oncology’s (“ESMO”) Brea...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch